A Phase 2 interventional study of Tremelimumab monotherapy and MEDI4736 monotherapy in Urothelial Bladder Cancer, Triple-negative Breast Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by AstraZeneca. Completed at 14 sites in 5 countries. Open to participants aged 18 Years to 150 Years. Per ClinicalTrials.gov, last updated 2023-11-15.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Triple Negative Breast Neoplasms by AstraZeneca — 1 open to participants now, 6 under way, 1 of them phase 3. Triple Negative Breast Neoplasms · AstraZeneca.
Among the 15 studies in Triple Negative Breast Neoplasms by AstraZeneca, this one is the 11th largest by enrollment, is one of 2 that started in 2015, is one of 3 in phase 2, and was the 5th registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →1 of the 15 studies in Triple Negative Breast Neoplasms by AstraZeneca is open now, in 4 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Australia, Japan and 1 more country
Ages 18+
By country, each count listing its studies:
Of the 331 Triple Negative Breast Neoplasms studies recruiting now, 231 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 150 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 1
First in 2008; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is close to the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 99 across the 15 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Triple Negative Breast Neoplasms by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors
This is an open-label, multi-center study to determine the efficacy and safety of tremelimumab in the treatment of different cohorts of patients with selected advanced solid tumors. If eligible and at the discretion of the Investigator, after confirmed disease progression on tremelimumab monotherapy or during follow-up, patients will have the option of being sequenced to MEDI4736 (MedImmune 4736) monotherapy or MEDI4736 + tremelimumab combination therapy, for up to 12 months or until disease progression, whichever comes sooner.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
tremelimumab monotherapy, with the option for eligible patients to be sequenced to MEDI4736 monotherapy or MEDI4736 + tremelimumab combination therapy after progressive disease (PD)
Biological: Tremelimumab monotherapy · Biological: MEDI4736 monotherapy · Biological: MEDI4736 + tremelimumab combination therapy
IV infusion
IV infusion
Drug pages: Durvalumab · Tremelimumab
IV infusion
Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase
Objective response rate (ORR) during the initial tremelimumab monotherapy phase was assessed by the site Investigator using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) and was defined as the percentage of patients with a confirmed overall response of complete response (CR) or partial response (PR) and was based on all treated patients who had measurable disease at baseline (Day 1). 95% confidence intervals (CIs) were calculated using the Clopper Pearson method.
Time frame: From baseline to 12 months in the tremelimumab monotherapy phase
Median Duration of Response (DoR) During Tremelimumab Monotherapy Phase
DoR during the initial tremelimumab monotherapy phase was assessed by the site Investigator using RECIST 1.1 and was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The time of the initial response was defined as the latest of the dates contributing toward the first visit response of CR or PR. If a patient did not progress following a response, then their DoR was censored at the progression-free survival (PFS) censoring time. DoR was not defined for those patients who did not have documented response. Median DoR was calculated using the Kaplan-Meier technique.
Time frame: From baseline to 12 months in the tremelimumab monotherapy phase
Disease Control Rate (DCR) During Tremelimumab Monotherapy Phase
DCR during the initial tremelimumab monotherapy phase was defined as the percentage of patients who had a best objective response (BoR) of CR or PR in the first 3 months (PDAC patients) or 4 months (UBC and TNBC patients) and 12 months (all patients), or who had demonstrated stable disease (SD) for a minimum interval of 3, 4 or 12 months following the start of study treatment. DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event. 95% CIs were calculated using the Clopper Pearson method.
Time frame: From baseline to 12 months in the tremelimumab monotherapy phase
Median PFS During Tremelimumab Monotherapy Phase
PFS during the initial tremelimumab monotherapy phase was assessed by the site Investigator using RECIST 1.1 and was defined as the time from the date of enrollment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from therapy or received another anticancer therapy prior to progression. Progression events that did not occur within 3 months (PDAC patients) or 4 months (UBC/TNBC patients) of the last evaluable assessment (or first dose) were censored. Median PFS was calculated using the Kaplan-Meier technique.
Time frame: From baseline to 12 months in the tremelimumab monotherapy phase
Best Objective Response (BoR) During Tremelimumab Monotherapy Phase
BoR during the initial tremelimumab monotherapy phase was calculated based on the overall visit responses from each RECIST 1.1 assessment and was defined as the best response a patient had during their time in the study (from CR, PR, SD, PD or not evaluable \[NE\]) obtained among all tumor assessment visits from baseline until end of treatment or determination of PD. The BoR was summarized by percentage of patients for each category (CR, PR, SD, PD, and NE).
Time frame: From baseline to 12 months in the tremelimumab monotherapy phase
Median Overall Survival (OS) During Tremelimumab Monotherapy Phase
OS was defined as the time from the date of first dose until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. OS is presented from start of tremelimumab monotherapy phase and includes the retreatment phase if the patient entered the corresponding treatment phase. Median OS was calculated using the Kaplan-Meier technique.
Time frame: From baseline to final data cut-off date
Percentage of Patients With Confirmed Overall Response During Retreatment Phase
ORR was assessed by the site Investigator using RECIST 1.1 and was defined as the percentage of patients with a confirmed overall response of CR or PR and was based on all treated patients who had measurable disease at baseline (Day 1) and who sequenced to durvalumab monotherapy (MEDI treatment phase) or durvalumab + tremelimumab combination therapy (COMBO treatment phase). 95% CIs were calculated using the Clopper Pearson method.
Time frame: From baseline to 12 months in retreatment phase
Median DoR During Retreatment Phase
DoR during the retreatment phase was assessed by the site Investigator using RECIST 1.1 and was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The time of the initial response was defined as the latest of the dates contributing toward the first visit response of CR or PR. If a patient did not progress following a response, then their DoR was censored at the PFS censoring time. DoR was not defined for those patients who did not have documented response. Median DoR was calculated using the Kaplan-Meier technique.
Time frame: From baseline to 12 months in retreatment phase
DCR During Retreatment Phase
DCR during the retreatment phase was defined as the percentage of patients who had a BoR of CR or PR in the first 3 months (PDAC patients) or 4 months (UBC and TNBC patients) or who had demonstrated SD for a minimum interval of 3 or 4 months following the start of study treatment. DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event. 95% CIs were calculated using the Clopper Pearson method.
Time frame: From baseline to 4 months in retreatment phase
Median PFS During Retreatment Phase
PFS during the retreatment phase was assessed by the site Investigator using RECIST 1.1 and defined as the time from the date of enrollment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from therapy or received another anticancer therapy prior to progression. Progression events that did not occur within 3 months (PDAC patients) or 4 months (UBC/TNBC patients) of the last evaluable assessment (or first dose) were censored. Median PFS was calculated using the Kaplan-Meier technique.
Time frame: From baseline to 12 months in retreatment phase
BoR During Retreatment Phase
BoR during the retreatment phase was calculated based on the overall visit responses from each RECIST 1.1 assessment and was defined as the best response a patient had during their time in the study (from CR, PR, SD, PD or NE) obtained among all tumor assessment visits from baseline until end of treatment or determination of PD. The BoR was summarized by percentage of patients for each category (CR, PR, SD, PD, and NE).
Time frame: From baseline to 12 months in retreatment phase
Median OS During Retreatment Phase
OS during the retreatment phase was defined as the time from the date of first dose until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique.
Time frame: From baseline in retreatment phase to final data cut-off date
A total of 64 patients with select advanced solid tumors were treated in this phase II, open-label, multi-center study from November 2015. Primary data cut off date: 17 February 2018. Final data cut off date: 31 December 2018.
| Milestone | UBC Cohort | TNBC Cohort | PDAC Cohort |
|---|---|---|---|
| Started | 32 | 12 | 20 |
| Started retreatment phase (combo) | 7 | 5 | 4 |
| Started retreatment phase (medi) | 4 | 0 | 1 |
| Completed | 4 | 1 | 0 |
| Not completed | 28 | 11 | 20 |
| Withdrew: Lost to follow-up | 2 | 2 | 0 |
| Withdrew: Death | 19 | 6 | 17 |
| Withdrew: Withdrawal by subject | 5 | 3 | 3 |
| Withdrew: Reason not specified | 1 | 0 | 0 |
| Withdrew: Site closure | 1 | 0 | 0 |
Objective response rate (ORR) during the initial tremelimumab monotherapy phase was assessed by the site Investigator using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) and was defined as the percentage of patients with a confirmed overall response of complete response (CR) or partial response (PR) and was based on all treated patients who had measurable disease at baseline (Day 1). 95% confidence intervals (CIs) were calculated using the Clopper Pearson method.
| Percentage of Patients | UBC - Tremelimumab Monotherapy | TNBC - Tremelimumab Monotherapy | PDAC - Tremelimumab Monotherapy |
|---|---|---|---|
| Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase | 18.8 (7.2 to 36.4) | 8.3 (0.2 to 38.5) | 0.0 (0.0 to 16.8) |
DoR during the initial tremelimumab monotherapy phase was assessed by the site Investigator using RECIST 1.1 and was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The time of the initial response was defined as the latest of the dates contributing toward the first visit response of CR or PR. If a patient did not progress following a response, then their DoR was censored at the progression-free survival (PFS) censoring time. DoR was not defined for those patients who did not have documented response. Median DoR was calculated using the Kaplan-Meier technique.
| Months | UBC - Tremelimumab Monotherapy | TNBC - Tremelimumab Monotherapy | PDAC - Tremelimumab Monotherapy |
|---|---|---|---|
| Median Duration of Response (DoR) During Tremelimumab Monotherapy Phase | NA (NA to NA) | 12.9 (12.9 to 12.9) | NA (NA to NA) |
DCR during the initial tremelimumab monotherapy phase was defined as the percentage of patients who had a best objective response (BoR) of CR or PR in the first 3 months (PDAC patients) or 4 months (UBC and TNBC patients) and 12 months (all patients), or who had demonstrated stable disease (SD) for a minimum interval of 3, 4 or 12 months following the start of study treatment. DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event. 95% CIs were calculated using the Clopper Pearson method.
| Percentage of patients | UBC - Tremelimumab Monotherapy | TNBC - Tremelimumab Monotherapy | PDAC - Tremelimumab Monotherapy |
|---|---|---|---|
| DCR at 3 or 4 months | 25.0 (11.46 to 43.40) | 8.3 (0.21 to 38.48) | 0.0 (0.00 to 16.84) |
| DCR at 12 months | 21.9 (9.28 to 39.97) | 8.3 (0.21 to 38.48) | 0.0 (0.00 to 16.84) |
PFS during the initial tremelimumab monotherapy phase was assessed by the site Investigator using RECIST 1.1 and was defined as the time from the date of enrollment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from therapy or received another anticancer therapy prior to progression. Progression events that did not occur within 3 months (PDAC patients) or 4 months (UBC/TNBC patients) of the last evaluable assessment (or first dose) were censored. Median PFS was calculated using the Kaplan-Meier technique.
| Months | UBC - Tremelimumab Monotherapy | TNBC - Tremelimumab Monotherapy | PDAC - Tremelimumab Monotherapy |
|---|---|---|---|
| Median PFS During Tremelimumab Monotherapy Phase | 2.63 (1.77 to NA) | 3.58 (1.40 to 4.04) | 1.77 (1.38 to 2.92) |
BoR during the initial tremelimumab monotherapy phase was calculated based on the overall visit responses from each RECIST 1.1 assessment and was defined as the best response a patient had during their time in the study (from CR, PR, SD, PD or not evaluable \[NE\]) obtained among all tumor assessment visits from baseline until end of treatment or determination of PD. The BoR was summarized by percentage of patients for each category (CR, PR, SD, PD, and NE).
| Percentage of Patients | UBC - Tremelimumab Monotherapy | TNBC - Tremelimumab Monotherapy | PDAC - Tremelimumab Monotherapy |
|---|---|---|---|
| CR | 6.3 | 0.0 | 0.0 |
| PR | 12.5 | 8.3 | 0.0 |
| SD | 9.4 | 0.0 | 0.0 |
| PD | 68.8 | 91.7 | 90.0 |
| NE | 3.1 | 0.0 | 10.0 |
OS was defined as the time from the date of first dose until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. OS is presented from start of tremelimumab monotherapy phase and includes the retreatment phase if the patient entered the corresponding treatment phase. Median OS was calculated using the Kaplan-Meier technique.
| Months | UBC - Tremelimumab Monotherapy | TNBC - Tremelimumab Monotherapy | PDAC - Tremelimumab Monotherapy |
|---|---|---|---|
| Median Overall Survival (OS) During Tremelimumab Monotherapy Phase | 10.32 (5.91 to 24.61) | 12.88 (2.53 to NA) | 3.98 (2.83 to 5.13) |
ORR was assessed by the site Investigator using RECIST 1.1 and was defined as the percentage of patients with a confirmed overall response of CR or PR and was based on all treated patients who had measurable disease at baseline (Day 1) and who sequenced to durvalumab monotherapy (MEDI treatment phase) or durvalumab + tremelimumab combination therapy (COMBO treatment phase). 95% CIs were calculated using the Clopper Pearson method.
| Percentage of Patients | UBC - COMBO | TNBC - COMBO | PDAC - COMBO | UBC- MEDI | PDAC - MEDI |
|---|---|---|---|---|---|
| Percentage of Patients With Confirmed Overall Response During Retreatment Phase | 0.0 (0.0 to 41.0) | 0.0 (0.0 to 52.2) | 0.0 (0.0 to 60.2) | 25.0 (0.6 to 80.6) | 0.0 (0.0 to 97.5) |
DoR during the retreatment phase was assessed by the site Investigator using RECIST 1.1 and was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression. The time of the initial response was defined as the latest of the dates contributing toward the first visit response of CR or PR. If a patient did not progress following a response, then their DoR was censored at the PFS censoring time. DoR was not defined for those patients who did not have documented response. Median DoR was calculated using the Kaplan-Meier technique.
| Months | UBC - COMBO | TNBC - COMBO | PDAC - COMBO | UBC- MEDI | PDAC - MEDI |
|---|---|---|---|---|---|
| Median DoR During Retreatment Phase | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 7.3 (7.3 to 7.3) | NA (NA to NA) |
DCR during the retreatment phase was defined as the percentage of patients who had a BoR of CR or PR in the first 3 months (PDAC patients) or 4 months (UBC and TNBC patients) or who had demonstrated SD for a minimum interval of 3 or 4 months following the start of study treatment. DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event. 95% CIs were calculated using the Clopper Pearson method.
| Percentage of Patients | UBC - COMBO | TNBC - COMBO | PDAC - COMBO | UBC- MEDI | PDAC - MEDI |
|---|---|---|---|---|---|
| DCR During Retreatment Phase | 28.6 (3.67 to 70.96) | 20.0 (0.51 to 71.64) | 25.0 (0.63 to 80.59) | 25.0 (0.63 to 80.59) | 0.0 (0.00 to 97.50) |
PFS during the retreatment phase was assessed by the site Investigator using RECIST 1.1 and defined as the time from the date of enrollment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from therapy or received another anticancer therapy prior to progression. Progression events that did not occur within 3 months (PDAC patients) or 4 months (UBC/TNBC patients) of the last evaluable assessment (or first dose) were censored. Median PFS was calculated using the Kaplan-Meier technique.
| Months | UBC - COMBO | TNBC - COMBO | PDAC - COMBO | UBC- MEDI | PDAC - MEDI |
|---|---|---|---|---|---|
| Median PFS During Retreatment Phase | 2.83 (1.81 to 3.65) | 0.99 (0.92 to NA) | 2.86 (1.87 to 3.52) | 2.86 (1.81 to 6.62) | 1.84 (1.84 to 1.84) |
BoR during the retreatment phase was calculated based on the overall visit responses from each RECIST 1.1 assessment and was defined as the best response a patient had during their time in the study (from CR, PR, SD, PD or NE) obtained among all tumor assessment visits from baseline until end of treatment or determination of PD. The BoR was summarized by percentage of patients for each category (CR, PR, SD, PD, and NE).
| Percentage of Patients | UBC - COMBO | TNBC - COMBO | PDAC - COMBO | UBC- MEDI | PDAC - MEDI |
|---|---|---|---|---|---|
| CR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| PR | 0.0 | 0.0 | 0.0 | 25.0 | 0.0 |
| SD | 14.3 | 20.0 | 0.0 | 0.0 | 0.0 |
| PD | 71.4 | 80.0 | 100.0 | 75.0 | 100.0 |
| NE | 14.3 | 0.0 | 0.0 | 0.0 | 0.0 |
OS during the retreatment phase was defined as the time from the date of first dose until death due to any cause. Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive. Median OS was calculated using the Kaplan-Meier technique.
| Months | UBC - COMBO | TNBC - COMBO | PDAC - COMBO | UBC- MEDI | PDAC - MEDI |
|---|---|---|---|---|---|
| Median OS During Retreatment Phase | 11.86 (5.91 to NA) | 33.05 (9.69 to 33.05) | 7.18 (3.98 to 18.76) | 16.53 (7.56 to 32.39) | 4.14 (NA to NA) |
Collected over Adverse events were collected from Day 1 (i.e. first dose) up until 90 days following the end of treatment in the tremelimumab monotherapy phase and the retreatment phase (up to a total of 15 months per treatment phase).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| UBC- Tremelimumab Monotherapy | 13/32 (40.6%) | 18/32 (56.3%) | 30/32 (93.8%) |
| TNBC - Tremelimumab Monotherapy | 4/12 (33.3%) | 4/12 (33.3%) | 10/12 (83.3%) |
| PDAC- Tremelimumab Monotherapy | 12/20 (60%) | 11/20 (55%) | 19/20 (95%) |
| UBC - COMBO | 4/7 (57.1%) | 3/7 (42.9%) | 7/7 (100%) |
| TNBC - COMBO | 2/5 (40%) | 2/5 (40%) | 5/5 (100%) |
| PDAC - COMBO | 4/4 (100%) | 3/4 (75%) | 4/4 (100%) |
| UBC- MEDI | 4/4 (100%) | 1/4 (25%) | 4/4 (100%) |
| PDAC - MEDI | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Event | UBC- Tremelimumab Monotherapy | TNBC - Tremelimumab Monotherapy | PDAC- Tremelimumab Monotherapy | UBC - COMBO | TNBC - COMBO | PDAC - COMBO | UBC- MEDI | PDAC - MEDI |
|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/32 | 0/12 | 0/20 | 0/7 | 0/5 | 0/4 | 1/4 | 0/1 |
| DiarrhoeaGastrointestinal disorders | 4/32 | 0/12 | 3/20 | 0/7 | 0/5 | 1/4 | 0/4 | 0/1 |
| Large intestinal obstructionGastrointestinal disorders | 0/32 | 0/12 | 0/20 | 0/7 | 0/5 | 1/4 | 0/4 | 0/1 |
| Jaundice cholestaticHepatobiliary disorders | 0/32 | 0/12 | 0/20 | 0/7 | 0/5 | 1/4 | 0/4 | 0/1 |
| EncephalopathyNervous system disorders | 0/32 | 0/12 | 0/20 | 0/7 | 0/5 | 1/4 | 0/4 | 0/1 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/32 | 0/12 | 1/20 | 0/7 | 0/5 | 1/4 | 0/4 | 0/1 |
| Diarrhoea haemorrhagicGastrointestinal disorders | 0/32 | 0/12 | 0/20 | 0/7 | 1/5 | 0/4 | 0/4 | 0/1 |
| AstheniaGeneral disorders | 0/32 | 0/12 | 0/20 | 1/7 | 1/5 | 0/4 | 0/4 | 0/1 |
| HyponatraemiaMetabolism and nutrition disorders | 0/32 | 2/12 | 0/20 | 0/7 | 0/5 | 0/4 | 0/4 | 0/1 |
| Confusional statePsychiatric disorders | 1/32 | 0/12 | 0/20 | 1/7 | 0/5 | 0/4 | 0/4 | 0/1 |
| Event | UBC- Tremelimumab Monotherapy | TNBC - Tremelimumab Monotherapy | PDAC- Tremelimumab Monotherapy | UBC - COMBO | TNBC - COMBO | PDAC - COMBO | UBC- MEDI | PDAC - MEDI |
|---|---|---|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 4/32 | 2/12 | 2/20 | 0/7 | 1/5 | 1/4 | 0/4 | 1/1 |
| AstheniaGeneral disorders | 0/32 | 0/12 | 1/20 | 1/7 | 0/5 | 2/4 | 0/4 | 1/1 |
| DizzinessNervous system disorders | 1/32 | 1/12 | 0/20 | 0/7 | 0/5 | 0/4 | 0/4 | 1/1 |
| Decreased appetiteMetabolism and nutrition disorders | 7/32 | 2/12 | 5/20 | 1/7 | 4/5 | 1/4 | 0/4 | 0/1 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 0/32 | 2/12 | 0/20 | 0/7 | 3/5 | 0/4 | 0/4 | 0/1 |
| HyponatraemiaMetabolism and nutrition disorders | 1/32 | 2/12 | 3/20 | 0/7 | 2/5 | 2/4 | 0/4 | 0/1 |
| FatigueGeneral disorders | 15/32 | 1/12 | 6/20 | 2/7 | 0/5 | 0/4 | 1/4 | 0/1 |
| ConstipationGastrointestinal disorders | 9/32 | 5/12 | 3/20 | 0/7 | 1/5 | 1/4 | 0/4 | 0/1 |
| PruritusSkin and subcutaneous tissue disorders | 8/32 | 5/12 | 7/20 | 1/7 | 2/5 | 1/4 | 0/4 | 0/1 |
| Weight decreasedInvestigations | 4/32 | 0/12 | 2/20 | 0/7 | 2/5 | 0/4 | 0/4 | 0/1 |
Analysis was performed on the FAS (all treated patients who received at least 1 dose of tremelimumab monotherapy).
| Age, Categorical(Participants) | UBC Cohort | TNBC Cohort | PDAC Cohort | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 13 | 8 | 14 | 35 |
| >=65 years | 19 | 4 | 6 | 29 |
| Sex: Female, Male(Participants) | UBC Cohort | TNBC Cohort | PDAC Cohort | Total |
|---|---|---|---|---|
| Female | 6 | 12 | 9 | 27 |
| Male | 26 | 0 | 11 | 37 |
| Ethnicity (NIH/OMB)(Participants) | UBC Cohort | TNBC Cohort | PDAC Cohort | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 31 | 12 | 20 | 63 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | UBC Cohort | TNBC Cohort | PDAC Cohort | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 10 | 11 | 11 | 32 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 |
| White | 21 | 1 | 8 | 30 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Nov 2015 to primary completion in Feb 2018, 27 months.
Results were first posted in Mar 2019, 1 year after primary completion.
Of 255 phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 94. This study's 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tremelimumab
Triple Negative Breast Neoplasms →